Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000649.
Tumor ablation techniques, like cryoablation, are successfully used in the clinic to treat tumors. The tumor debris remaining in situ after ablation is a major antigen depot, including neoantigens, which are presented by dendritic cells (DCs) in the draining lymph nodes to induce tumor-specific CD8 T cells. We have previously shown that co-administration of adjuvants is essential to evoke strong in vivo antitumor immunity and the induction of long-term memory. However, which adjuvants most effectively combine with in situ tumor ablation remains unclear.
Here, we show that simultaneous administration of cytidyl guanosyl (CpG) with saponin-based adjuvants following cryoablation affects multifunctional T-cell numbers and interleukin (IL)-1 induced polymorphonuclear neutrophil recruitment in the tumor draining lymph nodes, relative to either adjuvant alone. The combination of CpG and saponin-based adjuvants induces potent DC maturation (mainly CpG-mediated), antigen cross-presentation (mainly saponin-based adjuvant mediated), while excretion of IL-1β by DCs in vitro depends on the presence of both adjuvants. Most strikingly, CpG/saponin-based adjuvant exposed DCs potentiate antigen-specific T-cell proliferation resulting in multipotent T cells with increased capacity to produce interferon (IFN)γ, IL-2 and tumor necrosis factor-α in vitro. Also in vivo the CpG/saponin-based adjuvant combination plus cryoablation increased the numbers of tumor-specific CD8 T cells showing enhanced IFNγ production as compared with single adjuvant treatments.
Collectively, these data indicate that co-injection of CpG with saponin-based adjuvants after cryoablation induces an increased amount of tumor-specific multifunctional T cells. The combination of saponin-based adjuvants with toll-like receptor 9 adjuvant CpG in a cryoablative setting therefore represents a promising in situ vaccination strategy.
肿瘤消融技术,如冷冻消融,在临床上被成功用于治疗肿瘤。消融后残留在原位的肿瘤碎片是一个主要的抗原储存库,包括新抗原,这些新抗原由引流淋巴结中的树突状细胞 (DC) 呈递,从而诱导肿瘤特异性 CD8 T 细胞。我们之前已经表明,佐剂的共同给药对于引发强烈的体内抗肿瘤免疫和诱导长期记忆是至关重要的。然而,哪种佐剂与原位肿瘤消融最有效地结合仍不清楚。
在这里,我们表明,冷冻消融后同时给予胞苷鸟苷 (CpG) 和基于皂素的佐剂会影响肿瘤引流淋巴结中多功能 T 细胞的数量和白细胞介素 (IL)-1 诱导的多形核中性粒细胞募集,与单独使用任一佐剂相比。CpG 和基于皂素的佐剂的组合诱导强烈的 DC 成熟(主要由 CpG 介导)、抗原交叉呈递(主要由基于皂素的佐剂介导),而体外 DC 分泌的 IL-1β依赖于两种佐剂的存在。最引人注目的是,CpG/基于皂素的佐剂暴露的 DC 增强了抗原特异性 T 细胞的增殖,导致体外具有增加的产生干扰素 (IFN)γ、IL-2 和肿瘤坏死因子-α的能力的多能 T 细胞。同样在体内,CpG/基于皂素的佐剂联合加冷冻消融增加了肿瘤特异性 CD8 T 细胞的数量,与单一佐剂治疗相比,这些细胞表现出增强的 IFNγ 产生。
总的来说,这些数据表明,冷冻消融后 CpG 与基于皂素的佐剂的共同注射诱导了更多数量的肿瘤特异性多功能 T 细胞。因此,在冷冻消融环境中,基于皂素的佐剂与 Toll 样受体 9 佐剂 CpG 的联合代表了一种有前途的原位疫苗接种策略。